China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Minnesota Alzheimer's patients will be among the first to receive a new treatment through the drug Kisunla, which targets the ...

The Eli Lilly drug called donanemab – and sold under the brand name, Kisunla – is the second monoclonal antibody infusion available in the United States and covered by Medicare. Studies have ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...